Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia

Expression of uPAR (CD87) may play a relevant role in the diagnosis and pathophysiology and prognostic pattern of acute myeloid leukemia. The aims of this study were to find out the prognostic significance of pretreatment detection of CD87 and study the prevalence of CD87 expression and its value as...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2012-09, Vol.29 (3), p.2063-2069
Main Authors: Atfy, Maha, Eissa, Mohamad, Salah, Hossam E., El Shabrawy, Deena A.
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers, Tumor - analysis
Female
Flow Cytometry
Hematology
Humans
Internal Medicine
Kaplan-Meier Estimate
Leukemia
Leukemia, Myeloid, Acute - metabolism
Leukemia, Myeloid, Acute - mortality
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Paper
Pathology
Prognosis
Receptors, Urokinase Plasminogen Activator - biosynthesis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Expression of uPAR (CD87) may play a relevant role in the diagnosis and pathophysiology and prognostic pattern of acute myeloid leukemia. The aims of this study were to find out the prognostic significance of pretreatment detection of CD87 and study the prevalence of CD87 expression and its value as a predictor for survival in AML patients. CD87 expression has been studied on blasts in 110 newly diagnosed AML patients. Immunophenotyping and cytogenetic analysis of these cases were performed. CD87 was positive in 80 (72.7%) cases of patients. The MFI categorized the expression of CD87 into CD87 High and CD87 Low expression. Blast cells show that monocytic differentiation has a significantly more CD87 High expression than CD87 Low expression. Cytogenetic abnormalities were found in 58.7% of patients with CD87 Low AML and 41.25% of patients with CD87 High AML. Cases with CD87 High expression cells were characterized by a significantly lower survival period especially when co-expressed with CD56, CD34, and/or CD64. There is a negative prognostic influence of the expression of CD87 on the surface of AML blasts, but more tests are necessary to explain the pathophysiological mechanisms behind these findings and to learn about the mechanism that influences the CD87 expression and function.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-011-9993-x